149 related articles for article (PubMed ID: 23800093)
21. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective.
Bargetzi MJ; Passweg J; Baertschi E; Schoenenberger A; Gwerder C; Tichelli A; Burger J; Mingrone W; Herrmann R; Gratwohl A; Wernli M
Bone Marrow Transplant; 2003 Jan; 31(2):99-103. PubMed ID: 12621490
[TBL] [Abstract][Full Text] [Related]
22. Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma.
Kiefer T; Krüger WH; Montemurro M; Schüler F; Hirt C; Pasold R; Niederwieser D; Schwenke M; Dölken G
Transfusion; 2008 Dec; 48(12):2624-8. PubMed ID: 18801020
[TBL] [Abstract][Full Text] [Related]
23. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA
Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
[TBL] [Abstract][Full Text] [Related]
24. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
25. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
26. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
[TBL] [Abstract][Full Text] [Related]
27. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield.
Duong HK; Bolwell BJ; Rybicki L; Koo A; Hsi ED; Figueroa P; Dean R; Pohlman B; Kalaycio M; Andresen S; Sobecks R; Copelan E
J Clin Apher; 2011; 26(3):111-5. PubMed ID: 21647951
[TBL] [Abstract][Full Text] [Related]
28. The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients.
Damiani D; Grimaz S; Sperotto A; Geromin A; Skert C; Cerno M; Rinaldi C; Fanin R
Adv Clin Path; 2002 Jan; 6(1):11-6. PubMed ID: 17582943
[TBL] [Abstract][Full Text] [Related]
29. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
[TBL] [Abstract][Full Text] [Related]
30. Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation.
Chow S; Lazo-Langner A; Ormond G; Howson-Jan K; Xenocostas A
J Clin Apher; 2013 Aug; 28(4):285-92. PubMed ID: 23426584
[TBL] [Abstract][Full Text] [Related]
31. [Clinical study on high-dose etoposide with granulocyte colony-stimulating factor for mobilization of autologous peripheral blood stem cells in patients with hematologic malignancies].
Shen WY; Li JY; Hong M; Zhang R; Lu H; Liu P; Qian SX; Xu W; Qiu HX; Wu HX
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):628-31. PubMed ID: 23134856
[TBL] [Abstract][Full Text] [Related]
32. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost.
Boeve S; Strupeck J; Creech S; Stiff PJ
Bone Marrow Transplant; 2004 May; 33(10):997-1003. PubMed ID: 15064690
[TBL] [Abstract][Full Text] [Related]
33. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
[TBL] [Abstract][Full Text] [Related]
34. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
Akhtar S; Tbakhi A; Humaidan H; El Weshi A; Rahal M; Maghfoor I
Bone Marrow Transplant; 2006 Feb; 37(3):277-82. PubMed ID: 16400345
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study.
Han X; Ma L; Zhao L; He X; Liu P; Zhou S; Yang J; Qin Y; Yang S; Yao J; Shi Y
J Clin Apher; 2012; 27(2):64-74. PubMed ID: 22298390
[TBL] [Abstract][Full Text] [Related]
36. Polymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies.
Szmigielska-Kaplon A; Szemraj J; Hamara K; Robak M; Wolska A; Pluta A; Czemerska M; Krawczynska A; Jamroziak K; Szmigielska K; Robak T; Wierzbowska A
Biol Blood Marrow Transplant; 2014 Jul; 20(7):986-91. PubMed ID: 24680978
[TBL] [Abstract][Full Text] [Related]
37. Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review.
Ozkan HA; Bal C; Gulbas Z
Eur J Haematol; 2014; 92(5):390-7. PubMed ID: 24400988
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
39. The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF.
Hacıoğlu S; Sarı I; Doğu MH; Keskin A
Transfus Apher Sci; 2014 Feb; 50(1):71-4. PubMed ID: 24342458
[TBL] [Abstract][Full Text] [Related]
40. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
